{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:32:44Z","timestamp":1790343164084,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008586","name":"Stiftelsen Professor Bror Gadelius Minnesfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008586","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>During the first year following electroconvulsive therapy (ECT) for major depressive disorder (MDD) there is a large risk of relapse. Previous studies have shown favourable results for lithium after ECT for MDD. However, lithium is infrequently prescribed after ECT. While some evidence exists for other pharmacological strategies such as TCAs and TCA-lithium combinations, comparative data remain limited. The aim of this study was to explore pharmacological treatments after ECT for MDD and analyse their association with relapse following response to ECT for MDD. We hypothesized that lithium would be associated with a lower risk of relapse. We conducted a nationwide cohort study using data from Swedish registers. Patients 18 years or older with MDD who received ECT 2013-2019 and responded distinctly to ECT were followed for a year. Specified drugs dispensed up to four weeks after the ECT series were considered the exposure. Relapse was defined as psychiatric hospitalisation, renewed ECT, intentional self-harm, or death by suicide. Adjusted hazard ratios (aHR) and 95% confidence intervals (CI) were estimated using Cox models controlled for several potential confounders. The study population included 2 858 patients with distinct response to ECT. The most common psychiatric drugs dispensed after ECT were antipsychotics (39.7%), mirtazapine (38.0%), and selective serotonin reuptake inhibitors (SSRI) (35.9%). There was a statistically non-significant lower risk of relapse associated with lithium (aHR 0.86, 95% CI 0.69-1.07, p\u2009=\u20090.17). Antipsychotics were associated with a greater risk of relapse (aHR 1.17, 95% CI 1.05-1.31, p\u2009=\u20090.006). For other pharmacological treatments there were no associations with risk of relapse.<\/jats:p>","DOI":"10.1038\/s41398-025-03746-0","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T19:14:53Z","timestamp":1763493293000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world analysis of pharmacological treatments to prevent relapse after electroconvulsive therapy for major depressive disorder: A nationwide cohort study"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2382-2651","authenticated-orcid":false,"given":"Alexander","family":"Kronsell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7454-3065","authenticated-orcid":false,"given":"Axel","family":"Nordenskj\u00f6ld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2198-8842","authenticated-orcid":false,"given":"Robert","family":"Bod\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellenor","family":"Mittendorfer-Rutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1372-4262","authenticated-orcid":false,"given":"Johan","family":"Reutfors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9769-324X","authenticated-orcid":false,"given":"Marios","family":"Rossides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8495-8125","authenticated-orcid":false,"given":"Mikael","family":"Tiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"3746_CR1","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/S0140-6736(03)12705-5","volume":"361","author":"UK ECT Review Group.","year":"2003","unstructured":"UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet Lond Engl. 2003;361:799\u2013808.","journal-title":"Lancet Lond Engl"},{"key":"3746_CR2","unstructured":"American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. American Psychiatric Association, 2010 https:\/\/psychiatryonline.org\/pb\/assets\/raw\/sitewide\/practice_guidelines\/guidelines\/mdd.pdf."},{"key":"3746_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1192\/bjp.2017.28","volume":"212","author":"L van Diermen","year":"2018","unstructured":"van Diermen L, van den Ameele S, Kamperman AM, et al. Prediction of electroconvulsive therapy response and remission in major depression: meta-analysis. Br J Psychiatry J Ment Sci. 2018;212:71\u201380.","journal-title":"Br J Psychiatry J Ment Sci"},{"key":"3746_CR4","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1038\/npp.2013.149","volume":"38","author":"A Jelovac","year":"2013","unstructured":"Jelovac A, Kolshus E, McLoughlin DM. Relapse following successful electroconvulsive therapy for major depression: a meta-analysis. Neuropsychopharmacology. 2013;38:2467\u201374.","journal-title":"Neuropsychopharmacology"},{"key":"3746_CR5","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1001\/jama.285.10.1299","volume":"285","author":"HA Sackeim","year":"2001","unstructured":"Sackeim HA, Haskett RF, Mulsant BH, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA. 2001;285:1299\u2013307.","journal-title":"JAMA"},{"key":"3746_CR6","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1177\/104012371402600407","volume":"26","author":"NA Youssef","year":"2014","unstructured":"Youssef NA, McCall WV. Relapse prevention after index electroconvulsive therapy in treatment-resistant depression. Ann Clin Psychiatry J Am Acad Clin Psychiatr. 2014;26:288\u201396.","journal-title":"Ann Clin Psychiatry J Am Acad Clin Psychiatr"},{"key":"3746_CR7","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1056\/NEJMct075234","volume":"357","author":"SH Lisanby","year":"2007","unstructured":"Lisanby SH. Electroconvulsive therapy for depression. N Engl J Med. 2007;357:1939\u201345.","journal-title":"N Engl J Med"},{"key":"3746_CR8","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1176\/appi.ajp.2016.16010118","volume":"173","author":"CH Kellner","year":"2016","unstructured":"Kellner CH, Husain MM, Knapp RG, et al. A novel strategy for continuation ECT in geriatric depression: phase 2 of the PRIDE study. Am J Psychiatry. 2016;173:1110\u20138.","journal-title":"Am J Psychiatry"},{"key":"3746_CR9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/YCT.0b013e318276591f","volume":"29","author":"A Nordenskj\u00f6ld","year":"2013","unstructured":"Nordenskj\u00f6ld A, von Knorring L, Ljung T, Carlborg A, Brus O, Engstr\u00f6m I. Continuation electroconvulsive therapy with pharmacotherapy versus pharmacotherapy alone for prevention of relapse of depression: a randomized controlled trial. J ECT. 2013;29:86\u201392.","journal-title":"J ECT"},{"key":"3746_CR10","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1192\/bjp.139.4.284","volume":"139","author":"A Coppen","year":"1981","unstructured":"Coppen A, Abou-Saleh MT, Milln P, et al. Lithium continuation therapy following electroconvulsive therapy. Br J Psychiatry J Ment Sci. 1981;139:284\u20137.","journal-title":"Br J Psychiatry J Ment Sci"},{"key":"3746_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/YCT.0b013e31826ea8c4","volume":"29","author":"J Prudic","year":"2013","unstructured":"Prudic J, Haskett RF, McCall WV, et al. Pharmacological strategies in the prevention of relapse after electroconvulsive therapy. J ECT. 2013;29:3\u201312.","journal-title":"J ECT"},{"key":"3746_CR12","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1192\/bjo.2019.37","volume":"5","author":"O Brus","year":"2019","unstructured":"Brus O, Cao Y, Hammar \u00c5, et al. Lithium for suicide and readmission prevention after electroconvulsive therapy for unipolar depression: population-based register study. BJPsych Open. 2019;5:e46.","journal-title":"BJPsych Open"},{"key":"3746_CR13","doi-asserted-by":"publisher","first-page":"935","DOI":"10.4088\/JCP.v68n0617","volume":"68","author":"NA Crossley","year":"2007","unstructured":"Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry. 2007;68:935\u201340.","journal-title":"J Clin Psychiatry"},{"key":"3746_CR14","doi-asserted-by":"publisher","first-page":"f3646","DOI":"10.1136\/bmj.f3646","volume":"346","author":"A Cipriani","year":"2013","unstructured":"Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013;346:f3646.","journal-title":"BMJ"},{"key":"3746_CR15","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S2215-0366(17)30134-7","volume":"4","author":"J Tiihonen","year":"2017","unstructured":"Tiihonen J, Tanskanen A, Hoti F, et al. Pharmacological treatments and risk of readmission to hospital for unipolar depression in Finland: a nationwide cohort study. Lancet Psychiatry. 2017;4:547\u201353.","journal-title":"Lancet Psychiatry"},{"key":"3746_CR16","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1017\/S0033291722001246","volume":"52","author":"Y Yan","year":"2022","unstructured":"Yan Y, Yang X, Wang M, Chen B, Yin L, Ma X. Efficacy and acceptability of second-generation antipsychotics with antidepressants in unipolar depression augmentation: a systematic review and network meta-analysis. Psychol Med. 2022;52:2224\u201331.","journal-title":"Psychol Med"},{"key":"3746_CR17","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1001\/jama.2019.10517","volume":"322","author":"AJ Flint","year":"2019","unstructured":"Flint AJ, Meyers BS, Rothschild AJ, et al. Effect of continuing olanzapine vs placebo on relapse among patients with psychotic depression in remission. JAMA. 2019;322:622\u201331.","journal-title":"JAMA"},{"key":"3746_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/acps.13628","volume":"149","author":"A Al-Wandi","year":"2024","unstructured":"Al-Wandi A, Land\u00e9n M, Nordenskj\u00f6ld A. Antipsychotics in the maintenance phase for psychotic depression. Acta Psychiatr Scand. 2024;149:6\u201317.","journal-title":"Acta Psychiatr Scand"},{"key":"3746_CR19","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/acps.13277","volume":"143","author":"S Lambrichts","year":"2021","unstructured":"Lambrichts S, Detraux J, Vansteelandt K, et al. Does lithium prevent relapse following successful electroconvulsive therapy for major depression? a systematic review and meta-analysis. Acta Psychiatr Scand. 2021;143:294\u2013306.","journal-title":"Acta Psychiatr Scand"},{"key":"3746_CR20","unstructured":"Elvin T, Nordenskj\u00f6ld A Annual Report Q-ECT 2019. \u00d6rebro, 2020."},{"key":"3746_CR21","unstructured":"von Knorring L Kvalitetsregister ECT \u00c5rsrapport 2013. \u00d6rebro, 2013."},{"key":"3746_CR22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1080\/08039488.2021.1939416","volume":"76","author":"I Ahmad","year":"2022","unstructured":"Ahmad I, Sandberg M, Brus O, et al. Validity of diagnoses, treatment dates, and rating scales in the Swedish national quality register for electroconvulsive therapy. Nord J Psychiatry. 2022;76:96\u2013103.","journal-title":"Nord J Psychiatry"},{"key":"3746_CR23","unstructured":"OSF Registries | Comparative effectiveness of pharmacological treatments to maintain response after electroconvulsive therapy for major depressive disorder. https:\/\/osf.io\/r3awy (accessed May 10, 2024)."},{"key":"3746_CR24","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.4103\/sja.SJA_543_18","volume":"13","author":"S Cuschieri","year":"2019","unstructured":"Cuschieri S. The STROBE guidelines. Saudi J Anaesth. 2019;13:S31\u20134.","journal-title":"Saudi J Anaesth"},{"key":"3746_CR25","unstructured":"Guy W Clinical Global Impressions. In: ECDEU assessment manual for psychopharmacology. Rockville, MD: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976: 217\u20139."},{"key":"3746_CR26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0165-0327(00)00242-1","volume":"64","author":"P Svanborg","year":"2001","unstructured":"Svanborg P, Asberg M. A comparison between the beck depression inventory (BDI) and the self-rating version of the montgomery asberg depression rating scale (MADRS). J Affect Disord. 2001;64:203\u201316.","journal-title":"J Affect Disord"},{"key":"3746_CR27","volume":"2011","author":"A Nordenskj\u00f6ld","year":"2011","unstructured":"Nordenskj\u00f6ld A, von Knorring L, Engstr\u00f6m I. Predictors of time to relapse\/recurrence after electroconvulsive therapy in patients with major depressive disorder: a population-based cohort study. Depress Res Treat. 2011;2011:470985.","journal-title":"Depress Res Treat"},{"key":"3746_CR28","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1111\/j.1742-1241.2007.01416.x","volume":"61","author":"A Tschoner","year":"2007","unstructured":"Tschoner A, Engl J, Laimer M, et al. Metabolic side effects of antipsychotic medication. Int J Clin Pr. 2007;61:1356\u201370.","journal-title":"Int J Clin Pr"},{"key":"3746_CR29","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2147\/NDT.S198774","volume":"16","author":"D Voineskos","year":"2020","unstructured":"Voineskos D, Daskalakis ZJ, Blumberger DM. Management of Treatment-Resistant Depression: Challenges and Strategies. Neuropsychiatr Dis Treat. 2020;16:221.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"3746_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/(SICI)1520-6394(1998)7:1+<11::AID-DA4>3.0.CO;2-I","volume":"7","author":"IM Anderson","year":"1998","unstructured":"Anderson IM. SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety. 1998;7:11\u20137.","journal-title":"Depress Anxiety"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03746-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03746-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03746-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T09:47:41Z","timestamp":1764582461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03746-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3746"],"URL":"https:\/\/doi.org\/10.1038\/s41398-025-03746-0","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"1 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"514"}}